Corrigendum: Survival Motor Neuron (SMN) protein is required for normal mouse liver development (Scientific Reports (2016) 6 (34635) DOI: 10.1038/srep34635);Survival Motor Neuron (SMN) protein is required for normal mouse liver development

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Szunyogova, Eva ^a,b   Zhou, Haiyan ^c   Maxwell, Gillian K ^a   Powis, Rachael A ^b   Francesco, Muntoni ^c   Gillingwater, Thomas H ^b   Parson, Simon H ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SMN1 PROTEIN, MOUSE; SURVIVAL MOTOR NEURON PROTEIN 1;

ANIMAL; DISEASE MODEL; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; KNOCKOUT MOUSE; LIVER; METABOLISM; MOUSE; PATHOLOGY; SPINAL MUSCULAR ATROPHY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LIVER; MICE; MICE, KNOCKOUT; MUSCULAR ATROPHY, SPINAL; SURVIVAL OF MOTOR NEURON 1 PROTEIN;

EID: 84989842794     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35898     Document Type: Erratum

References (76)

1. Werdnig, G. Two early infantile hereditary cases of progressive muscular atrophy simulating dystrophy, but on a neural basis. Arch. Psychiat. Nurs. 22, 437-481 (1891).
2. Hoffmann, J. Familial spinal muscular atrophy in infancy. Dtsch. Z. Nervenheilkd. 3, 427-470 (1892).
3. Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 80, 155-165 (1995).
4. Burghes, A. H. M. & Beattie, C. E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci. 10, 597-609 (2009).
5. Hamilton, G. & Gillingwater, T. H. Spinal muscular atrophy: going beyond the motor neuron. Trends. Mol. Med. 19, 40-50 (2013).
6. Shababi, M., Lorson, C. L. & Rudnik-Shoneborn, S. S. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J. Anat. 224, 15-28 (2014).
7. Ottesen, E. W. et al. Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy. Sci. Rep. 6, 20193 (2016).
8. Moller, P. et al. Spinal muscular atrophy type I combined with atrial septal defect in three sibs. Clin. Genet. 38, 81-83 (1990).
9. Burglen, L. et al. Survival motor neuron gene deletion in the arthrogryposis multiplex congenital-spinal muscular atrophy association. Lancet. 346, 316-317 (1995).
10. Mulleners, W. M. et al. Spinal Muscular Atrophy Combined with Congenital Heart Disease: A Report of Two Cases. Neuropediatrics. 27, 333-334 (1996).
11. Rudnik-SchOneborn, S. et al. Apparent autosomal recessive inheritance in families with proximal spinal muscular atrophy affecting individuals in two generations. Am. J. Hum. Geneti. 59, 1163-1165 (1996).
12. Jong, Y. J., Chang, J. G. & Wu, J. R. Large-scale deletions in a Chinese infant associated with a variant form of Werdnig-Hoffmann disease. Neurology. 51, 878-879 (1998).
13. Cook, A. L., Curzon, C. L. & Milazzo, A. S. An infant with hypoplastic left heart syndrome and spinal muscular atrophy. Cardiol. Young. 16, 78-80 (2006).
14. Sarnat, H. B. & Trevenen, C. L. Motor neuron degeneration in a 20-week male fetus: spinal muscular atrophy type 0. Can. J. Neurol. Sci. 34, 215-220 (2007).
15. Vaidla, E. et al. Neonatal Spinal Muscular Atrophy Type 1 With Bone Fractures and Heart Defect. J. Child. Neurol. 22, 67-70 (2007).
16. Menke, L. A. et al. Congenital heart defects in spinal muscular atrophy type I: a clinical report of two siblings and a review of the literature. Am. J. Med. Genet. 146(A), 740-744 (2008).
17. Rudnik-SchOneborn, S. et al. Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J. Med. Genet. 45, 635-638 (2008).
18. Shababi, M. et al. Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum. Mol. Genet. 19, 4059-4071 (2010).
19. Bogdanik, L. P. et al. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy. PNAS. 112, E5863-E5872 (2015).
20. Distefano, G. et al. Heart involvement in progressive spinal muscular atrophy. A review of the literature and case histories in childhood. Pediatr. Med. Chir. 16, 125-128 (1994).
21. El-Matary, W., Kotagiri, S., Cameron, D. & Peart, T. Spinal muscle atrophy type 1 (Werdnig-Hoffman disease) with complex cardiac malformation. Eur. J. Pediatr. 163, 331-332 (2004).
22. Bach, J. R. Medical considerations of long-term survival of Werdnig-Hoffmann disease. Am. J. Phys. Med. Rehab. 86, 349-355 (2007).
23. Collado-Ortiz, M. A., Shkurovich-Bialik, P., González-De Leo, A. & Arch-Tirado, E. Type I spinal atrophy (Werdnig-Hoffman disease). Case report. Cirugía. Y. Cirujanos. 75, 119-122 (2007).
24. Bevan, A. K. et al. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum. Mol. Genet. 19, 3895-3905 (2010).
25. Heier, C. R., Satta, R., Lutz, C. & DiDonato, C. J. Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Hum. Mol. Genet. 19, 3906-3918 (2010).
26. Shababi, M. et al. Partial restoration of cardio-vascular defects in a rescued severe model of spinal muscular atrophy. J. Mol. Cell. Cardiol. 52, 1074-1082 (2012).
27. Somers, E., Stencel, Z., Wishart, T. M., Gillingwater, T. H. & Parson, S. H. Density, calibre and ramification of muscle capillaries are altered in a mouse model of severe spinal muscular atrophy. Neuromuscular Disord. 22, 435-442 (2012).
28. Somers, E. et al. Vascular defects and spinal cord hypoxia in spinal muscular atrophy. Ann. Neurol. 79, 217-230 (2016).
29. Swoboda, K. J. et al. Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy. PLoS One. 4, e5268 (2009).
30. Rudnik-Shoneborn, S. et al. Digital necroses and vascular thrombosis in severe spinal muscular atrophy. Muscle Nerve. 42, 144-147 (2010).
31. Araujo, A. p., Araujo, M. & Swoboda, K. J. Vascular Perfusion Abnormalities in Infants with Spinal Muscular Atrophy. J. Pediatr. 155, 292-294 (2009).
32. Zaworski, P. et al. SMN Protein Can Be Reliably Measured in Whole Blood with an Electrochemiluminescence (ECL) Immunoassay: Implications for Clinical Trials. PLoS One. 11, e0150640 (2016).
33. Coovert, D. D. et al. The Survival Motor Neuron Protein in Spinal Muscular Atrophy. Hum. Mol. Genet. 6, 1205-1214 (1997).
34. Machlus, K. R. & Italiano, J. E. Jr. The incredible journey: From megakaryocyte development to platelet formation. J. Cell. Biol. 201, 785-796 (2013).
35. Vitte, J. M. et al. Deletion of Murine Smn Exon 7 Directed to Liver Leads to Severe Defect of Liver Development Associated with Iron Overload. Am. J. Pathol. 165, 1731-1741 (2004).
36. Hua, Y. et al. Peripheral SMN restoration is essential for long-term rescue of a severe SMA mouse model. Nature. 478, 123-126 (2011).
37. Hentze, M. W. et al. Two to tango: regulation of Mammalian iron metabolism. Cell. 142, 24-38 (2010).
38. Parker, G. C., Carruthers, N. J., Gratsch, T., Caruso, J. A. & Stemmer, P. M. Proteomic profile of embryonic stem cells with low survival motor neuron protein is consistent with developmental dysfunction. J. Neural Transm. doi: 10.1007/s00702-016-1520-y (2016).
39. Moritz, K. M., Lim, G. B. & Wintour, E. M. Developmental regulation of erythropoietin and erythropoiesis. Am. J. Physiol. 273, R1829-R1844 (1997).
40. Madureira, P. A. et al. The role of the annexin A2 heterotetramer in vascular fibrinolysis. Blood. 118, 4789-4797 (2011).
41. Wang, C., Guo, Y., Wang, J. & Min, Z. Annexin A2 knockdown inhibits hepatoma cell growth and sensitizes hepatoma cells to 5-fluorouracil by regulating β -catenin and cyclin D1 expression. Mol. Med. Rep. 11, 2147-2152 (2015).
42. Shafey, D., Boyer, J. G., Bhanot, K. & Kothary, R. Identification of Novel Interacting Protein Partners of SMN Using Tandem Affinity Purification. J. Proteome Res. 9, 1659-1669 (2010).
43. Zhang, Z. et al. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell. 133, 585-600 (2008).
44. Zhou, H. et al. A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe SMA Transgenic Mice. Hum. Gene Ther. 24, 331-342 (2013).
45. Sintusek, P. et al. Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment. PLos One. 11, e0155032 (2016).
46. Ayres-Silva, J. P., Manso, P. P. D., Madeira, M. R. D., Pelajo-Machado, M. & Lenzi, H. L. Sequential morphological characteristics of murine fetal liver hematopoietic microenvironment in Swiss Webster mice. Cell Tissue Res. 344, 455-469 (2011).
47. Guo, Y. et al. Relationships between Hematopoiesis and Hepatogenesis in the Midtrimester Fetal Liver Characterized by Dynamic Transcriptomic and Proteomic Profiles. PLoS One. 4, e7641 (2009).
48. Crawford, L. W., Foley, J. F. & Elmore, S. A. Histology Atlas of the Developing Mouse Hepatobiliary System with Emphasis on Embryonic Days 9.5-18.5. Toxicol. Pathol. 38, 872-906 (2010).
49. Nayak, N. C. & Mital, I. The dynamics of a -fetoprotein and albumin synthesis in human and rat liver during normal ontogeny. Am. J. Pathol. 86, 359-374 (1977).
50. Ebert, A. D. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature. 457, 277-280 (2009).
51. Vaisman, B., Fibach, E. & Konijn, A. M. Utilization of Intracellular Ferritin Iron for Hemoglobin Synthesis in Developing Human Erythroid Precursors. Blood. 90, 831-838 (1997).
52. Jeong, S. Y. et al. Iron insufficiency compromises motor neurons and their mitochondrial function in Irp2-null mice. PLoS One. 6, e25404 (2011).
53. Acsadi, G. et al. Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy. J. Neurosci. Res. 87, 2748-2756 (2009).
54. Ripolone, M. et al. Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy. JAMA Neurol. 72, 666-675 (2015).
55. Xu, C. C., Denton, K. R., Wang, Z. B., Zhang, X. & Li, X. J. Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy. Dis. Model. Mech. 9, 39-49 (2016).
56. Dachs, E., Hereu, M., Piedrafita, L., Casanovas, A., Caldero, J. & Esquerda, J. E. Defective Neuromuscular Junction Organization and Postnatal Myogenesis in Mice With Severe Spinal Muscular Atrophy. J. Neuropath. Exp. Neur. 70, 444-461 (2011).
57. Thomson, A. K. et al. SMN protein is required for the normal postnatal development of the spleen. J. Anat. (2016) In Press.
58. Glassman, A. B. Platelet abnormalities in hepatobiliary diseases. Ann. Clin. Lab. Sci. 20, 119-122 (1990).
59. Hsieh-Li, H. M. et al. A mouse model for spinal muscular atrophy. Nat. Genet. 24, 66-70 (2000).
60. Tsai, L. K., Tsai, M. S., Lin, T. B., Hwu, W. L. & Li, H. Establishing a standardized therapeutic testing protocol for spinal muscular atrophy. Neurobiol. Dis. 24, 286-295 (2006).
61. Narver, H. L. et al. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann. Neurol. 64, 465-470 (2008).
62. Schreml, J. et al. Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585. Eur. J. Hum. Genet. 21, 643-652 (2013).
63. Ling, Q. et al. Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo. J. Clin. Invest. 113, 38-48 (2004).
64. Akashi, K., Traver, D., Miyamoto, T. & Weissman, I. L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 404, 193-197 (2000).
65. Manz, M. G., Miyamoto, T., Akashi, K. & Weissman, I. L. Prospective isolation of human clonogenic common myeloid progenitors. Proc. Natl. Acad. Sci. USA 99, 11872-11877 (2002).
66. Staropoli, J. F. et al. Rescue of gene-expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7. Genomics. 105, 220-228 (2015).
67. Wishart, T. M. et al. SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum. Mol. Genet. 19, 4216-4228 (2010).
68. Grice, S. J. & Liu, J. L. Survival Motor Neuron Protein Regulates Stem Cell Division, Proliferation, and Differentiation in Drosophila. PLoS Genet. 7, e1002030 (2011).
69. Murray, L. M. et al. Selective vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17, 949-962 (2008).
70. Singh, N. K., Singh, N. N., Androphy, E. J. & Singh, R. N. Splicing of critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol. 26, 1333-1346 (2006).
71. Porensky, P. N. et al. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum. Mol. Genet. 21, 1625-1638 (2012).
72. Mitrpant, C. et al. Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy. PLoS One. 8, e62114 (2013).
73. Zhou, H. et al. Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response. Hum Mol Genet. 24, 6265-6277 (2015).
74. Powis, R. A. et al. Systemic restoration of UBA1 ameliorates disease in spinal muscular atrophy. JCI Insight. 1, e87908 (2016).
75. Eaton, S. L. et al. A Guide to Modern Quantitative Fluorescent Western Blotting with Troubleshooting Strategies. J. Vis. Exp. 93, e52099 (2014).
76. Eaton, S. L. et al. Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. PLoS One. 8, e72457 (2013).